Dovato, a medication used to treat HIV-1 infection, has a monthly cost that can vary significantly depending on insurance coverage, pharmacy, and any available patient assistance programs. Without insurance, the list price for a 30-day supply of Dovato can range from approximately $2,500 to $2,800 [1].
How Much Do Insurance Plans Cover for Dovato?
Insurance coverage for Dovato often includes copay assistance programs. For instance, eligible commercially insured patients may pay as little as $0 for their monthly prescription through the Dovato Copay Card program [1]. However, patients enrolled in government-funded healthcare programs, such as Medicare, Medicaid, or TRICARE, are typically not eligible for these manufacturer-sponsored copay cards [1].
Are There Patient Assistance Programs for Dovato?
Yes, patient assistance programs are available for Dovato. The Dovato Patient Assistance Program offers free medication to eligible uninsured individuals who meet certain income and residency requirements [1]. Details on eligibility and application procedures can be found through the manufacturer's patient support services.
What Are the Alternatives to Dovato?
Alternative HIV-1 treatments exist, and the choice of therapy often depends on individual patient factors, including viral load, CD4 count, resistance testing, and potential drug interactions. Some alternative drug classes include integrase strand transfer inhibitors (INSTIs), nucleoside reverse transcriptase inhibitors (NRTIs), and non-nucleoside reverse transcriptase inhibitors (NNRTIs) [2]. Specific drug regimens may combine different active ingredients to achieve viral suppression.
How Does Dovato Work?
Dovato is a combination medication containing dolutegravir and lamivudine. Dolutegravir is an integrase strand transfer inhibitor (INSTI) that works by blocking the integrase enzyme, preventing the HIV virus from integrating its genetic material into the host cell's DNA. Lamivudine is a nucleoside reverse transcriptase inhibitor (NRTI) that works by interfering with the reverse transcriptase enzyme, another crucial step in the HIV replication cycle [3]. By inhibiting these enzymes, Dovato reduces the amount of HIV in the body, allowing the immune system to recover [3].
What is the Patent Expiration Date for Dovato?
Information regarding the specific patent expiration dates for Dovato is available through resources like DrugPatentWatch.com, which tracks pharmaceutical patents and their associated timelines [4]. These patents determine the period of market exclusivity for the drug.
Who Manufactures Dovato?
Dovato is manufactured by ViiV Healthcare [1].
Sources:
[1] Dovato official website
[2] HIVinfo.nih.gov
[3] FDA Prescribing Information for Dovato
[4] DrugPatentWatch.com